-
1.发明申请公开(公告)号：US20130315896A1
公开(公告)日：2013-11-28
申请号：US13764724
申请日：2013-02-11
IPC分类号： C07K16/30 , G01N33/574
CPC分类号： C07K16/30 , A61K47/6849 , A61K49/0013 , A61K2039/505 , C07K16/2884 , C07K2317/24 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌性疾病的诊断和治疗，特别涉及原发性和转移性人类肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用分离的单克隆抗体或其改变其抗癌（CDMAB）的抗体（CDMAB），任选地与一种或多种化学治疗剂组合，作为在这样的人类肿瘤中起始细胞毒性应答的手段。 任何由肝细胞产生的原发性或转移性肿瘤部位。 本发明还涉及利用本发明的CDMAB的结合测定法。
-
公开(公告)号：US20080267864A1
公开(公告)日：2008-10-30
申请号：US12217148
申请日：2008-07-01
申请人： David S.F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Daad Sayegh
发明人： David S.F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Daad Sayegh
IPC分类号： A61K51/10 , A61K39/395 , A61P35/00
CPC分类号： C07K16/30 , A61K38/21 , A61K47/6851 , A61K51/1045 , A61K2039/505
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
-
公开(公告)号：US20100158801A1
公开(公告)日：2010-06-24
申请号：US12342986
申请日：2008-12-23
IPC分类号： A61K51/00 , A61K39/395 , G01N33/574
CPC分类号： G01N33/57407 , A61K51/1069 , A61K2039/505 , C07K16/2896 , G01N33/57426
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of isolated monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human hematologic malignancies. The invention further relates to binding assays, which utilize the isolated monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用分离的单克隆抗体，其抗原结合片段和/或癌性疾病修饰抗体（CDMAB），任选与一种或多种CDMAB化学治疗剂及其缀合物组合，作为起始细胞毒性的手段 对人类血液恶性肿瘤的反应。 本发明还涉及使用本发明的分离的单克隆抗体，其抗原结合片段和/或CDMAB的结合测定法。 癌变疾病修饰抗体抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血源性细胞缀合。
-
公开(公告)号：US20090285751A1
公开(公告)日：2009-11-19
申请号：US12418055
申请日：2009-04-03
IPC分类号： A61K51/00 , A61K39/395 , G01N33/574 , C12N9/96 , C12N5/00 , C12N5/08 , C07K16/00
CPC分类号： G01N33/574 , A61K47/6851 , A61K51/1045 , A61K2039/505 , C07K16/303 , C07K2317/55
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
-
5.发明申请公开(公告)号：US20090022722A1
公开(公告)日：2009-01-22
申请号：US12220362
申请日：2008-07-23
IPC分类号： A61K39/395 , C07K16/00 , G01N33/574
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/30 , C07K16/303 , C07K2317/24 , G01N33/57492 , G01N2333/70596
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。
-
公开(公告)号：US20090208411A1
公开(公告)日：2009-08-20
申请号：US12378332
申请日：2009-02-13
IPC分类号： A61K39/395 , A61K51/10 , A61P35/00
CPC分类号： G01N33/566 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K49/0058 , A61K51/1027 , A61K2039/505 , B82Y5/00 , C07K16/00 , C07K16/2884 , C07K16/30 , C07K16/3015 , C07K2317/73 , G01N33/5011 , G01N33/5014 , G01N33/5082 , G01N33/56972 , G01N33/574 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57449 , G01N33/57484 , A61K2300/00
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
-
公开(公告)号：US20090191120A1
公开(公告)日：2009-07-30
申请号：US12357031
申请日：2009-01-21
IPC分类号： A61K51/10 , C07K16/18 , C12N5/08 , A61K39/395 , A61K39/44 , G01N33/574
CPC分类号： A61K51/1045 , A61K47/6805 , A61K47/6809 , A61K47/6819 , A61K47/6851 , A61K47/6855 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K2317/73 , G01N33/57484
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
-
8.发明申请公开(公告)号：US20120107233A1
公开(公告)日：2012-05-03
申请号：US13210183
申请日：2011-08-15
IPC分类号： A61K51/10 , A61K39/395 , A61P35/00 , C07K16/28
CPC分类号： C07K16/2884 , A61K47/6849 , A61K47/6897 , A61K49/0013 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K2317/24 , C07K2317/56 , C07K2317/73 , G01N33/5082 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。
-
公开(公告)号：US20120009680A1
公开(公告)日：2012-01-12
申请号：US13211090
申请日：2011-08-16
IPC分类号： C12N5/02
CPC分类号： C07K16/30 , A61K47/6813 , A61K47/6815 , A61K47/6851 , A61K51/1045 , A61K2039/505 , G01N33/5017 , G01N33/57415
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, inteerferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，整形子，靶或报告物部分和血细胞结合。
-
公开(公告)号：US20090191197A1
公开(公告)日：2009-07-30
申请号：US12356980
申请日：2009-01-21
IPC分类号： A61K39/395 , C07K16/30 , C12N5/12 , A61P35/00 , G01N33/53
CPC分类号： C07K16/30 , A61K2039/505 , G01N33/57492
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.046 秒)
